

ABATTIS ANNOUNCES PRIVATE PLACEMENT

Vancouver, BC – August 20, 2015 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), a Company that develops and commercializes natural health (nutraceutical) products and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical, nutraceutical, bioceutical and cosmetic markets - some of which will contain cannabinoid compounds, would like to announce the close of the private placement announced private placement of up to \$297,454.

Under the terms of the Private Placement, Abattis will issue up to 5,949,080 Units. Each Unit will consist of one Common Share at \$0.05 per share, and one full Share Purchase Warrant. One Warrant will be exercisable into one Common Share at a price of \$0.09 per Common Share. The expiry date for the exercise of the Warrants will be 24 months after the closing of this Unit Offering.

Proceeds of this offering will be used for the production and sale of hemp water, research and development, marketing, working capital, general corporate purposes. The Shares will be subject to a Canadian resale hold period expiring four months and one day from the closing.

Further, the Company is pleased to announce that, in compliance with the Company's option plan, the Company has granted 3,900,000 incentive stock options to certain of its directors, officers and consultants, with each option being exercisable into a common share of Abattis at \$0.06 per share for a period of five years.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company that aggregates, incubates, integrates and invests in the botanical drug development industry. The Company develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets – some of which will contain cannabinoid compounds. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD

"Bill Fleming"

Bill Fleming, CEO

For further information, contact the Company at (604) 336-0881 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual

Suite 1040 – 885 West Georgia Street,
Vancouver, BC V6C 3H1
Tel: 604.336.0881
Email: news@abattis.com



results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.